Study Finds No Trans d tropin Side Effects

Study on Trans-D Tropin side effects – Transdermal Growth Hormone Releasing Hormone (GHRH) Analog Efficacy Was Far Beyond Expectation.

Trans-D Tropin ® introduction:

  • Clinically tested using subjective SF-36 patient outcome based study parameters.
  • Continually undergoing randomized, multicentered, double blind, placebo controlled, cross-over studies monitoring numerous objective serum and urine parameters.
  • United States FDA registered with all ingredients GRAS classified. (National Drug Code # 65448-2115-1)
  • Applied transdermally by simply rubbing into skin.
  • Comprised of ingredients from non-animal sources, consisting of amino acids and fatty acids. All ‘active component’ ingredients are 100% natural.
  • Very affordable when compared to other treatment options.

ACCELERATED AND EFFICACIOUS RESULTS USING VARIABLE SOMATOTROPH SPECIFIC AND HYPOTHALAMOTROPH-SPECIFIC POLY-PEPTIDE COMBINANTS AS AN ALTERNATIVE TO ORAL GROWTH HORMONE SECRETAGOGUES AND RECOMBINANT HUMAN GROWTH HORMONE INJECTIONS

Rashid A. Buttar, DO, FAAPM    Dean C. Viktora, PhD    Michael E. Quinn, EMT-P

Abstract
Objective: We conducted a patient outcome based study investigating the possible efficacy of certain natural hypothalamotroph-specific poly-peptide combinants which appear to emulate the action of GHRH resulting in a more efficacious release of endogenous GH.

Background: Although the GH injections and secretagogues do offer many benefits for the limitations of aging, the need for a safer and more effective modality of therapy has long been warranted.

Methods: 35 patients were started on the study with 30 completing the study. The groups were divided into sedentary and athletic groups. A total of 22 subjective criteria were monitored including: sense of well being, overall energy, mental clarity, emotional stability, memory improvement, mood improvement, skin thickness, skin elasticity, wrinkle disappearance, new hair growth, skin texture, healing of old injuries, healing of overall injuries, range of motion, incidence of illness, body contour change, facial contour change, sexual frequency, sexual stamina, libido, quality of erection/arousal, and change in nocturia. Objective criteria measured were muscle strength, overall energy, exercise endurance and quality of sleep. Changes were recorded by a self-assessment methodology using a scale of -5 to +5 with 0 as base line. This accepted modality of evaluation with previous precedent having been set was chosen for this patient outcome based study. Laboratory data consisting of pre- and post- treatment IGF-1 levels and base line chemistries were also obtained.

Results: In less than one week, changes experienced were overwhelmingly positive. Improvements were reported of 282.98% in the female subjects and 352.38% in male subjects. Muscle strength increased by 81.0%. Endurance increased by 60.0%. Quality of sleep improved by 92.6%. Overall energy increased by 71.4%. Total mean improvement of all 4 objective criteria increased by 76.6%. Interestingly, the 3 week post study IGF-1 levels dropped 20.39% within both athletic and sedentary study groups with a 27.16% drop in IGF-1 levels in the female patients and a 14.61% drop in IGF-1 levels in the male patient population.

Conclusions: Efficacy was far beyond expectation. Objectively measured increases in muscular strength conclusively show this GHRH analog to be clinically superior for resistance training as compared to hGH injections. Simplicity of trans-dermal administration also appears to lead to a greater compliance. Substantial improvements in all criteria are further validation of Trans-D Tropin® ‘ as not only an effective alternative to hGH injections but perhaps a replacement of the more costly, potentially dangerous and less compliant injection treatments. The lack of correlation between clinical improvement and increasing IGF-1 levels also warrants re-evaluation of our currently accepted understanding of IGF-1 levels. The results of this study strongly warrant further clinical research of this GHRH analog.

Read the full study including references here … http://www.collegepharmacy.com/specializations/TransDTropinStudy.pdf